The Vancouver Prostate Centre is heavily focused on translational research, which is the ability to move laboratory discoveries through the checks and balances into clinical trials, and eventually to develop these research findings into new and more effective treatments.
PC-TRiADD is the Vancouver Prostate Centre’s Translational Research Initiative for Accelerated Discovery and Development.
This initiative dives down to the molecular level to understand prostate cancer progression and treatment resistance and uses that information to develop new services and products to improve cancer outcomes.
Previously funded by the Government of Canada as a Centre of Excellence for Commercialization and Research (CECR), PC-TRiADD also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research.
The UBC Faculty of Medicine posted a profile of the translational research breakthroughs being made at our Centre. "Translating research to treat prostate cancer" features our Executive Director Dr. Gleave and discusses the innovative potential therapeutics discovered by Drs. Rennie, Cherkasov and Zoubeidi.
Updated October 20, 2020
Research2Reality interview with Dr. Gleave
Dr. Gleave discusses the role of research in the development of new drug combinations and personalized treatments for prostate cancer on Research2Reality's Orange Chair Sessions (2.5 minutes).
